BP denied a report its embattled chief executive would leave soon as the company lined up $7 billion in asset sales to help pay for the worst oil spill in U.S. history.
CEO Tony Hayward, who has been heavily criticized for his handling of the disaster, had the full support of the board and would stay in office, a BP spokesman said, dismissing a report in the Times that he would step down within the next 10 weeks.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
